Last updated: May 23, 2026
Executive summary: Omnipaque 70 (iohexol 70 mgI/mL) is a branded, nonionic iodinated contrast media (ICM) product used for CT, angiography, and other radiographic imaging. The clinical-trials and market story is shaped less by disease-area innovation and more by (1) ongoing safety/real-world utilization studies for iodinated contrast, (2) supply-chain reliability and formulary access in radiology, and (3) competitive pressure from generic and private-label iohexol and other ICM classes. Near-term growth is primarily volume- and site-of-care-driven, while pricing remains constrained by substitution and contracting dynamics. Patent exclusivity is typically limited to formulation/packaging or specific method claims for branded products, while the active ingredient iohexol is long off-patent in most major markets.
What clinical trials update exists for Omnipaque 70 (iohexol 70 mgI/mL)?
Answer: There is no public signal of a new, Omnipaque-70-specific pivotal trial program in late-stage development. Publicly visible clinical activity around iodinated contrast in general is more commonly structured as post-marketing safety studies, comparative imaging/contrast effectiveness studies, and risk mitigation work (renal risk, hypersensitivity, extravasation).
Where do Omnipaque 70 studies show up: post-marketing and imaging outcomes
Iodinated contrast studies commonly fall into four buckets that affect Omnipaque 70 utilization even without drug-substance novelty:
- Hypersensitivity and premedication strategies
- Acute kidney injury (AKI) risk and renal function screening workflows
- Extravasation and department-level management protocols
- Image quality comparisons (dose, injection protocols, scanner generation)
Typical endpoints used in iodinated contrast clinical studies
- Incidence of immediate hypersensitivity reactions
- Changes in serum creatinine or AKI staging
- Need for rescue medication after mild/moderate reactions
- Extravasation volume thresholds and local tissue outcomes
- Quantitative image quality metrics (attenuation, signal-to-noise ratio) and diagnostic adequacy
How to interpret “clinical-trials updates” for a contrast agent
For branded ICMs, the practical update is usually operational:
- Updated radiology protocols using contemporary hydration and screening guidance
- Updated adverse reaction reporting patterns tied to real-world use
- Study-driven adoption of injection rate and osmolality/dose tailoring
Business implication: Omnipaque 70’s evidence base tends to be “continuous” (safety and utilization) rather than “step-change” (new indication or regimen requiring new trials).
How big is the market for Omnipaque 70 (iodinated contrast) and what share does it have?
Answer: Omnipaque 70 sits in the broader iodinated contrast media market, which is sized by global CT and angiography procedure volumes. Branded share is under pressure from generic iohexol substitution and from alternative ICMs (low-osmolar and iso-osmolar products) that compete on formulary pricing and contract terms. Branded product performance usually maps to hospital buying patterns, not to market expansion driven by new clinical outcomes.
Market demand drivers
- Rising CT utilization per capita
- Growth of cardiovascular and oncology imaging volumes
- Increasing adoption of contrast-enhanced protocols in emergency care
- Aging populations raising imaging frequency
- Contracting and group purchasing organization (GPO) influence on which ICMs are stocked
Market constraints
- Tender and rebate pressure that compresses effective prices
- Switching behavior between equivalent-dose iohexol products
- Ongoing scrutiny of renal risk and contrast stewardship programs affecting ordering practices
Commercial reality for Omnipaque 70
Because Omnipaque 70’s active ingredient is iohexol, the differentiators in practice are:
- Packaging and readiness for department workflows
- Supply reliability and fill-finish consistency
- Formulary and payer contracting rather than novel pharmacology
What is the revenue outlook for Omnipaque 70 through 2028–2030?
Answer: Outlook is volume-led with price-headwinds. The most likely trajectory is mid-single-digit to low-double-digit growth in units with flat-to-low growth in net sales, depending on contract renewals and tender outcomes. In contrast media, unit growth can coexist with net price pressure because multiple equivalent alternatives compete in the same dosing band.
Projection logic (ICM-specific)
- Procedure volume growth: CT growth tends to lift iodinated contrast consumption.
- Formulary selection: Hospital formularies favor a limited set of ICMs through group contracts.
- Substitution risk: Generic iohexol and alternative ICMs can displace branded share.
- Utilization protocols: Contrast stewardship may reduce unnecessary imaging or adjust dose strategies, moderating demand growth.
Three-scenario net sales projection framework (qualitative)
- Base case: modest unit growth offset by low-to-moderate price decline.
- Downside: faster generic substitution or adverse contract terms reduce share.
- Upside: retention in large accounts and supply stability improve share versus smaller competitors.
Note: A numeric forecast requires product-level financials and country-level pricing, which are not provided in the prompt.
When does Omnipaque 70 lose exclusivity under major patent regimes?
Answer: Omnipaque 70’s core active ingredient (iohexol) is long off-patent. Branded exclusivity for Omnipaque-specific commercialization, where present, is typically limited to secondary IP such as packaging, concentration-specific compositions, or method claims tied to administration or manufacturing. Those “secondary” rights, where they exist, expire according to their own filing and grant timelines rather than to a single “Omnipaque 70 expires on X date” headline.
What to check for branded contrast products
- Orange Book listings for specific NDA products (if any) and listed patents by drug product, formulation, or use
- Late-life patents tied to:
- Container closure systems
- Specific concentration compositions
- Manufacturing or sterilization process variants
- Method-of-use claims (less common for ICMs than for anti-infectives or oncology)
What patents protect Omnipaque 70, and how broad is the estate?
Answer: The strongest risk shield for a branded contrast product typically comes from formulation/product packaging claims that are specific to the marketed presentation. The breadth of enforceability often narrows over time as generics cover the active ingredient and broadly match the concentration and route.
How to map patent coverage for a concentration like 70 mgI/mL
A structured patent estate for a branded iodinated contrast product usually splits into:
- Drug substance-independent claims (rare for ICMs once iohexol is free)
- Drug product claims (concentration, excipients, stabilization)
- Container/closure claims (bottle/vial and sealing features)
- Process claims (manufacturing steps that affect purity, stability, or particle control)
Enforcement posture in ICM
In practice, ICM litigation is less frequent than in blockbuster therapeutics, and disputes usually resolve around:
- Bioequivalence and composition equivalency
- Whether a claimed process or specific formulation detail is copied
- Whether a generic can lawfully market under the relevant regulatory pathway
What is the Orange Book status of Omnipaque 70 (iohexol 70 mgI/mL)?
Answer: The Orange Book (where applicable) would list patents for the specific Omnipaque NDA product and any listed drug product patents. For an active ingredient like iohexol, most key substance-level rights are expected to be expired, leaving only any remaining listed patents for product/formulation or method claims. Without a product-specific NDA identifier in the prompt, a precise Orange Book entry list cannot be reproduced.
What generic entry risks exist for Omnipaque 70?
Answer: Generic substitution risk is structurally high because iohexol is a known active ingredient with multiple sources, and hospitals often treat equivalent ICMs as interchangeable for practical ordering. The primary entry barrier is not pharmacology but:
- Contracting and tender selection
- Presentation-specific match (concentration, packaging)
- Any remaining product-specific IP that could block specific “versions” rather than the class
Most common pathways for displacement
- Tender-driven selection where multiple equivalents bid
- Switch from branded to generic iohexol when supply and rebates align
- Substitution to another ICM class if it improves procurement terms or clinician preference
How does Omnipaque 70 compare with other iohexol concentrations and alternative ICMs?
Answer: Omnipaque 70 competes within a narrow clinical interchange space where concentration, viscosity, osmolality, and dose volume matter operationally. Clinicians and radiology departments choose based on protocol:
- CT contrast dosing strategy (dose volume vs concentration)
- Injection rate and viscosity tolerance
- Patient renal risk workflow
- Institutional preference for specific ICM SKUs due to stocking and protocols
Competitive set categories
- Same-active competitors: Other iohexol concentration SKUs (generic and branded)
- Different-active ICM competitors: Other nonionic low-osmolar or iso-osmolar agents used for CT/angiography
- Non-contrast imaging protocols: Reduced contrast use in certain diagnostic pathways (protocol-level, not drug-level)
What patent litigation affects Omnipaque 70 or iohexol products?
Answer: The main business exposure from litigation for branded ICMs typically relates to:
- Objections to generic marketing based on remaining listed patents
- Settlements that permit launch of generics in exchange for agreed timelines, carve-outs, or licensing terms
Without a specific litigation docket list in the prompt, no case-specific filing dates, courts, or settlement terms can be reliably enumerated.
How does biosimilar or follow-on biologic risk apply to Omnipaque 70?
Answer: Biosimilar risk does not apply. Omnipaque 70 is a small-molecule contrast agent, not a biologic.
What manufacturing or IP barriers could slow generic substitution for Omnipaque 70?
Answer: Barriers are usually non-IP or secondary-IP:
- Supply capacity and QC stability for high-purity iodinated formulations
- Packaging line fit and sterility assurance to meet equivalence standards
- Any remaining concentration/formulation-specific patents, if present, that are version- and presentation-bound
Commercial projection summary: what matters most for investors and licensors
- Primary growth driver: imaging procedure volumes (especially CT).
- Primary downside driver: tender and rebate pressure reducing branded net price and share.
- Secondary driver: supply stability and contract retention at large imaging networks.
- IP reality: active ingredient rights for iohexol are effectively not the basis of long-term branded exclusivity; residual protection, if any, is likely limited to product/formulation/packaging.
Key Takeaways
- Omnipaque 70 clinical activity is more likely post-marketing safety and utilization protocol work than new pivotal trials.
- Market growth is primarily volume-led; branded net sales are constrained by generic iohexol substitution and contracting.
- The active ingredient iohexol is long off-patent; any continuing exclusivity is likely limited to secondary, product-specific claims.
- Near-term competitive risk is driven by procurement and tender dynamics rather than breakthrough pharmacology.
- Numerical revenue forecasts require product-level financial baselines and geography-specific pricing, which are not provided here.
FAQs
- What evidence supports the safety of iodinated contrast like Omnipaque 70 in patients with renal impairment?
- How do radiology departments decide between iohexol 300/350 and iohexol 70 mgI/mL concentration products?
- What procurement and contracting mechanisms most influence branded vs generic iodinated contrast market share?
- Do contrast stewardship programs reduce overall iodinated contrast demand, and how would that affect Omnipaque 70?
- What regulatory pathway do generic iohexol products typically use, and what information is required to establish equivalence?
References
- U.S. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed via FDA Orange Book database).
- European Medicines Agency (EMA). Public assessment reports and product information for iodinated contrast media containing iohexol. (Accessed via EMA product database).
- ACR Manual on Contrast Media. American College of Radiology. (Most recent edition).
- Lexicomp / Micromedex. Iohexol prescribing information and safety data summaries. (Database access).
